BSNERGY:
In Vivo Assessment of the Effect of CYP1A2 Inhibition and
The immunomodulatory drug agent pomalidomide has pleiotropic cytotoxic effects against multiple myeloma (MM) cells1, 2 in addition to antiproliferative,3, 4 antiangiogenic,5, 6, 7 and immunomodulatory activity.8, 9 Furthermore, pomalidomide has potent effects on key cytokines, including interleukin‐10, interferon‐γ, and tumor necrosis
方案定制